Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.



Tillotts Pharma AG announces a new sales organisation for its products in Switzerland

  • The new establishment is part of Tillotts ambitious expansion plans throughout Europe
  • The Swiss sales team will focus on meeting the needs of healthcare professionals offering service, support and an innovative portfolio
  • YaldigoTM 1600 mg (mesalazine) will be the next product to launch, recently acquired product DificlirTM (fidaxomicin) expected to drive sustainable growth for the company


RHEINFELDEN, Switzerland, 10.06.2021 – Tillotts Pharma AG (“Tillotts”), part of the
Japanese Zeria Group, today announced its new sales organisation in Switzerland. After having
its headquarter for more than 35 years in Switzerland, the gastrointestinal (GI) specialist starts
now actively promoting its products. The launch of YaldigoTM1600 mg, the highest strength
mesalazine tablet currently available on the market, and the recently acquired DificlirTM are
expected to boost Tillotts Switzerland sales.

Today Tillotts operates in 65 countries through its own affiliates and distributors. Over the last decade, the company built, through a combination of organic growth and various product acquisitions, a strong portfolio in the field of GI diseases and extended its presence in strategic markets.

“We are very proud to be able to strengthen our sales efforts in the Swiss home market now also. Establishing a Swiss sales organisation reflects our aspiring growth strategy for the coming years to extend our presence throughout Europe and beyond,” says Thomas A. Tóth von Kiskér, CEO of Tillotts Pharma.

Prior to the Swiss opening, Tillotts recently started its activities in Belgium, the Netherlands and Luxembourg, shaping its European network.

Tillotts is aiming to concentrate on the further commercialisation of existing products such as
EntocortTM (budesonide), a first-line treatment indicated for mild to moderate Crohn’s disease
and microscopic colitis as well as for ulcerative colitis (UC) and ColperminTM, a treatment for the
symptoms of Irritable Bowel Syndrome such as painful cramps and bloating. Furthermore, the
launch of YaldigoTM 1600 mg and the integration of DificlirTM will enhance the portfolio on the
Swiss market and lay the path in offering healthcare professionals innovative treatment
solutions. YaldigoTM 1600 mg is indicated for the induction and maintenance of mild to moderate
UC, whereas DificlirTM, a narrow-spectrum antibiotic, will fill a gap in the treatment of patients
suffering from Clostridoides difficile infections (CDI).

“Investing in marketing and medical activities in Switzerland represents an exciting new chapter for the company and stresses our commitment to explore commercial growth opportunities in core markets and offer localised services,” says Mattias Norrman, Chief Operations Officer at Tillotts. “The launch of YaldigoTM 1600 mg enhances our strong product portfolio for the digestive system and will help to address the unmet treatment needs for patients living with ulcerative colitis”, he further explains.


For more information, please contact:

Tillotts Pharma AG
Susi Teichmann
Senior Manager Corporate Communications
Phone: +41 61 935 2759

About Tillotts

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma
company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the
development, acquisition and commercialisation of innovative pharmaceutical products for the
digestive system. Tillotts successfully markets its own products for the treatment of IBD and
Clostridoides difficile infection (CDI) as well as in-licensed products in around 65 countries
through its affiliates within Europe and a network of gastroenterology-focused partners
throughout the world.

All trademarks used or mentioned here are protected by law. © Copyright Tillotts Pharma AG. All rights reserved.

For more information, please visit

About Zeria

Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit


Download high-resolution photos here